当前位置：药药网 / 数据中心 / 临床注释,变异和临床注释数据
羟考酮
临床注释ID
1451567040
药物名称(英)
oxycodone
变异单倍型
CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*21, CYP3A4*22, CYP3A4*23, CYP3A4*24, CYP3A4*26, CYP3A4*28, CYP3A4*29, CYP3A4*30, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34
基因
CYP3A4
证据级别
3
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Metabolism/PK
表现型类别
代谢/PK
分数
2.5
PMID计数
2
计数的证据
3
表现型
表现型(英)
最新日期
2022-01-13
URL
https://www.pharmgkb.org/clinicalAnnotation/1451567040
专业人口(英)
专业人口
临床等位基因
id等位基因注释文本
448 *20 Patients carrying the CYP3A4*20 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
447 *19 Patients carrying the CYP3A4*19 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
446 *18 Patients carrying the CYP3A4*18 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
445 *17 Patients carrying the CYP3A4*17 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
444 *16 Patients carrying the CYP3A4*16 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
443 *15 Patients carrying the CYP3A4*15 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
442 *14 Patients carrying the CYP3A4*14 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
441 *13 Patients carrying the CYP3A4*13 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
440 *12 Patients carrying the CYP3A4*12 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
439 *11 Patients carrying the CYP3A4*11 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
438 *10 Patients carrying the CYP3A4*10 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
437 *9 Patients carrying the CYP3A4*9 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
436 *8 Patients carrying the CYP3A4*8 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
435 *7 Patients carrying the CYP3A4*7 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
434 *6 Patients carrying the CYP3A4*6 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
433 *5 Patients carrying the CYP3A4*5 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
432 *4 Patients carrying the CYP3A4*4 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
431 *3 Patients carrying the CYP3A4*3 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
430 *2 Patients carrying the CYP3A4*2 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
429 *1 Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
12 *34 Patients carrying the CYP3A4*34 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
11 *33 Patients carrying the CYP3A4*33 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
10 *32 Patients carrying the CYP3A4*32 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
9 *31 Patients carrying the CYP3A4*31 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
8 *30 Patients carrying the CYP3A4*30 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
7 *29 Patients carrying the CYP3A4*29 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
6 *28 Patients carrying the CYP3A4*28 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
5 *26 Patients carrying the CYP3A4*26 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
4 *24 Patients carrying the CYP3A4*24 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
3 *23 Patients carrying the CYP3A4*23 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
2 *22 Patients carrying the CYP3A4*22 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
1 *21 Patients carrying the CYP3A4*21 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.
临床证据
id证据的ID总结
14619 1451566922 CYP3A4 *2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.
14605 1451647340 CYP3A4 *22 is associated with decreased metabolism of oxycodone as compared to CYP3A4 *1.
14604 1451566980 CYP3A4 *6 + *17 + *20 + *21 + *26 + *30 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.
临床病史
id类型评论
61 Update Added PMID 34480108 to evidence
60 Create Created

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:33068302000535
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3